Affibody is a biotechnology company developing next generation radiopharmaceuticals based on our proprietary Affibody® platform
Affibody is strategically focused on advancing our pipeline of radioligand therapeutics that offer a competitive advantage and significant opportunities to benefit cancer patients. Our pipeline also includes partnership programs in immunology.
event
10 Nov
7th Targeted Radiopharmaceuticals Summit EU 2025 November 10-12, 2025, Amesterdam, Netherlands
event
17 Nov
Jefferies 2025 London Healthcare Conference November 17-20, 2025, London, UK
There are currently no posts in the reports and events archive.
Regulatory
2025-10-24
Regulatory
2025-10-21
It is the competence and the engagement of all coworkers that make Affibody an inspiring and exciting place to work at. We know we reach much further in innovation, efficiency, and quality by having a work place where we as coworkers care for each other, are ambitious and know and value our own contribution to the end result.
